Clarithromycin significantly increases linezolid serum concentrations

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5418-5419

  Bolhuis, Mathieu S ^a   Van Altena, Richard ^a   Uges, Donald R A ^a   Van Der Werf, Tjip S ^a   Kosterink, Jos G W ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; LINEZOLID;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; HUMAN; LETTER; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SMEAR; SPUTUM CULTURE;

ACETAMIDES; ADULT; CHROMATOGRAPHY, LIQUID; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DRUG INTERACTIONS; HUMANS; MALE; OXAZOLIDINONES; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, PULMONARY;

EID: 78649639526     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00757-10     Document Type: Letter

References (11)

1. Alcalá, L., M. J. Ruiz-Serrano, C. Perez-Fernandez Turegano, D. Garcia De Viedma, M. Diaz-Infantes, M. Marin-Arriaza, and E. Bouza. 2003. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother. 47:416-417.
2. Alffenaar, J. W., J. G. Kosterink, R. van Altena, T. S. van der Werf, D. R. Uges, and J. H. Proost. 2010. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther. Drug Monit. 32:97-101.
3. Eberl, S., B. Renner, A. Neubert, M. Reisig, I. Bachmakov, J. Konig, F. Dorje, T. E. Murdter, A. Ackermann, H. Dormann, K. G. Gassmann, E. G. Hahn, S. Zierhut, K. Brune, and M. F. Fromm. 2007. Role of P-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46:1039-1049.
4. Gebhart, B. C., B. C. Barker, and B. A. Markewitz. 2007. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 27:476-479.
5. Harmelink, I. M., J. W. C. Alffenaar, A. M. A. Wessels, B. Greijdanus, and D. R. A. Uges. 2008. A rapid and simple liquid chromatography-tandem mass spectrometry method for the determination of linezolid in human serum. Eur. J. Hosp. Pharm. 14:5-8.
6. Koh, W. J., O. J. Kwon, H. Gwak, J. W. Chung, S. N. Cho, W. S. Kim, and T. S. Shim. 2009. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother. 64:388-391.
7. Park, I. N., S. B. Hong, Y. M. Oh, M. N. Kim, C. M. Lim, S. D. Lee, Y. Koh, W. S. Kim, D. S. Kim, W. D. Kim, and T. S. Shim. 2006. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 58:701-704.
8. Rodríguez, J. C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin, and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467.
9. Vinh, D. C., and E. Rubinstein. 2009. Linezolid: a review of safety and tolerability. J. Infect. 59(Suppl. 1):S59-S74.
10. von der Lippe, B., P. Sandven, and O. Brubakk. 2006. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases. J. Infect. 52:92-96.
11. World Health Organization. 2010. Treatment of tuberculosis: guidelines for national programmes, 4th edition. World Health Organization, Geneva, Switzerland.